Tremblay Cecile L, Hicks Jennifer L, Sutton Lorraine, Giguel Francoise, Flynn Theresa, Johnston Mary, Sax Paul E, Walker Bruce D, Hirsch Martin S, Rosenberg Eric S, D'Aquila Richard T
Massachusetts General Hospital and Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
AIDS. 2003 May 2;17(7):1086-9. doi: 10.1097/00002030-200305020-00021.
We studied 14 patients acutely infected with wild-type HIV, who underwent supervised treatment interruptions after initial antiretroviral treatment including lamivudine. Lamivudine resistance mutations emerged for the first time during supervised treatment interruptions in one patient. Resistance should be monitored in supervised treatment interruptions trials, because mutations may first be detected only after therapy is interrupted.